Mirna Therapeutics said this week that the US Patent and Trademark Office has issued a notice of allowance for claims in a company-controlled patent application related to the therapeutic use of the let-7 microRNA.
Mirna said that, along with collaborators at Yale University, it has shown that let-7 regulates "multiple cancer-related genes and pathways, influences the sensitivity of cancer cells to radiation and chemotherapy, and affects tumor development."
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
